Press release Biocartis Group NV: SeptiCyte® RAPID Receives 510(k) clearance by US FDA
November 30, 2021 11:40 ET
|
Biocartis NV
PRESS RELEASE: 30 November 2021, 17:40 CET SeptiCyte® RAPID Receives 510(k) clearance by US FDA Mechelen, Belgium, 30 November 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an...
Persbericht Biocartis Group NV: SeptiCyte® RAPID krijgt 510(k) clearance van de US FDA
November 30, 2021 11:40 ET
|
Biocartis NV
PERSBERICHT: 30 november 2021, 17:40 CET SeptiCyte® RAPID krijgt 510(k) clearance van de US FDA Mechelen, België, 30 november 2021 – Biocartis Group NV (de ‘Vennootschap’ of ‘Biocartis’), een...
Olaparib Reduces Organ Damage in Sepsis
September 13, 2021 10:00 ET
|
Experimental Biology and Medicine
WASHINGTON, Sept. 13, 2021 (GLOBE NEWSWIRE) -- A recently published article in Experimental Biology and Medicine (Volume 246, Issue 17, September, 2021) examines the role of olaparib in sepsis. The...
BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection
June 29, 2021 13:58 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
Jafron Biomedical Announces Global Advisory Board
June 21, 2021 07:00 ET
|
Jafron Biomedical Co.,Ltd.
ZHUHAI, China, June 21, 2021 (GLOBE NEWSWIRE) -- Jafron Biomedical, a pioneer in the blood purification industry, announced it's founding the Global Advisory Board, which includes the world’s top...
HelixBind Awarded $3MM NIH Grant to Support Testing of Its RaPID Diagnostic Platform for Invasive Infections Associated with Sepsis
June 17, 2021 08:30 ET
|
HelixBind
BOXBOROUGH, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis, announced today it...
Global Bloodstream Infection Testing Market to Garner a Revenue of $7,722.2 Million, Growing at a CAGR of 8.4% during 2019-2027 - [247 Pages] Absolute Report by Research Dive
March 24, 2021 09:45 ET
|
Research Dive
New York, USA, March 24, 2021 (GLOBE NEWSWIRE) -- According to a report published by Research Dive, the global bloodstream infection testing market is forecasted to garner a revenue of $7,722.2...
BioAegis Therapeutics Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia
September 03, 2020 21:42 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
FDA Grants HelixBind Breakthrough Device Designation for RaPID Sepsis Test
August 24, 2020 11:47 ET
|
HelixBind
BOXBOROUGH, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis, announced today it...
HelixBind Awarded $3MM Grant from NIH and Expands Clinical Advisory Board to Accelerate Development of Its Diagnostic Platform for Invasive Infections
June 10, 2020 10:29 ET
|
HelixBind
BOXBOROUGH, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- HelixBind, which is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis, announced today it...